International Conference on Harmonisation; Draft Guidance on M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk; Availability
Title: Eli Lilly and Company M7 Step 2 Review Comments for FDA June2013
Eli Lilly and Company - Comment
This is comment on Notice
International Conference on Harmonisation; Draft Guidance on M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk; Availability
View Comment
Attachments:
Eli Lilly and Company M7 Step 2 Review Comments for FDA June2013
Title:
Eli Lilly and Company M7 Step 2 Review Comments for FDA June2013
Related Comments
View AllPublic Submission Posted: 06/17/2013 ID: FDA-2013-D-0369-0005
Jun 14,2013 11:59 PM ET
Public Submission Posted: 06/06/2013 ID: FDA-2013-D-0369-0002
Jun 14,2013 11:59 PM ET
Public Submission Posted: 06/17/2013 ID: FDA-2013-D-0369-0012
Jun 14,2013 11:59 PM ET
Public Submission Posted: 06/17/2013 ID: FDA-2013-D-0369-0008
Jun 14,2013 11:59 PM ET
Public Submission Posted: 06/17/2013 ID: FDA-2013-D-0369-0014
Jun 14,2013 11:59 PM ET